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Intratumoral heterogeneity contributes to cancer drug resistance, but the underlying mechanisms are not understood. Single-cell analyses of patient-derived models and clinical samples from glioblastoma patients treated with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) demonstrate that tumor cells reversibly up-regulate or suppress mutant EGFR expression, conferring distinct cellular phenotypes to reach an optimal equilibrium for growth. Resistance to EGFR TKIs is shown to occur by elimination of mutant EGFR from extrachromosomal DNA. After drug withdrawal, reemergence of clonal EGFR mutations on extrachromosomal DNA follows. These results indicate a highly specific, dynamic, and adaptive route by which cancers can evade therapies that target oncogenes maintained on extrachromosomal DNA.
T he majority of targeted therapies have not produced substantial survival benefits for most cancer patients (1, 2) . A variety of resistance mechanisms have been described, including incomplete target suppression, secondsite mutations, and activation of alternative kinases to maintain signal flux to downstream effector pathways (1-3). Thus, most efforts are now aimed at developing better drugs or better drug combinations to more fully suppress the target oncogenes and their downstream signals. Changes in the cellular composition of tumors, particularly in response to targeted treatment, could facilitate such a resistance mechanism and thereby dictate patient response. In glioblastoma (GBM), the most common malignant primary brain cancer of adults, the epidermal growth factor receptor (EGFR) is frequently mutated, commonly giving rise to the constitutively active oncogenic variant EGFRvIII (4, 5) . EGFRvIII potently accelerates tumor growth by cell-autonomous and intercellular signaling mechanisms (6) , but it also makes tumor cells that express it more sensitive to EGFR tyrosine kinase inhibitors (TKIs) (7, 8) . In clinical GBM samples, the level of EGFRvIII protein expression varies widely among cells within the tumor mass (6, 9-15). The potential contribution of heterogeneous EGFRvIII expression to EGFR TKI resistance in GBM (16) ) demonstrated increased phosphatidylinositol 3-kinase-Akt-mammalian target of rapamycin (PI3K-Akt-mTOR) signaling (Fig. 1A and fig. S2 ), elevation in tumor cell proliferation by a factor of 4 ( Fig. 1B and fig. S2 ), a lower basal apoptotic rate by a factor of 15 ( Fig.  1C and fig. S2 ), and increased glucose uptake (Fig. 1D) (Fig. 1F) .
To determine the effect of an EGFR TKI on EGFRvIII population dynamics, mice bearing tumors were treated daily with oral erlotinib (150 mg per kg of weight). Erlotinib treatment initially caused 80% tumor shrinkage (response) (blue line in Fig. 1G ), shifting the composition of tumors from being predominantly EGFRvIII High to predominantly EGFRvIII Low tumor cells ( Fig.  1H and fig. S3 ). This shift in the EGFRvIII population dynamics was maintained, even after tumors developed resistance to continued erlotinib treatment (resistant) [ S4 ). Most important, in tumor tissue from GBM patients treated for 7 to 10 days with the EGFR/ HER2 inhibitor lapatinib, the relative fraction of EGFRvIII High tumor cells dramatically declined relative to each patient's pretreatment sample (Fig.  1, I and J). Of note, this analysis was confined to patients whose posttreatment tumor tissue showed reduced EGFR phosphorylation relative to the pretreatment sample. We did not detect any decrease in EGFRvIII level in the two available GBMs in which no decrease in phospho-EGFR was seen after lapatinib treatment. (19) . Erlotinib treatment completely suppressed this state transition and maintained the population in an EGFRvIII Low state, and it continued to do so long after any tumor cell death was observed ( fig. S5) .
To determine the mechanism by which GBM cells modulate EGFRvIII protein levels during erlotinib resistance, we generated a reversible EGFR TKI resistance model by continuous treatment of GBM cells with erlotinib in GBM39 cells in neurosphere culture, followed by drug withdrawal (Fig. 3 , A to C), and examined the level, sequence, and subnuclear localization of EGFRvIII DNA. EGFRvIII arises from an in-frame genomic deletion of exons 2 to 7 of the EGFR gene and has been thought to reside primarily on small circular extrachromosomal fragments of DNA called doubleminute (DM) chromosomes (20) (21) (22) . Fluorescent in situ hybridization (FISH) of naïve (n = 15 metaphases), erlotinib-resistant (n = 15 metaphases), and drug-removed (n = 10 metaphases) GBM39 metaphase cells with EGFR and centromere 7-specific DNA probes revealed abundant EGFR + extrachromosomal DNA in naïve and drugremoved tumor cells and a complete loss of these EGFR + extrachromosomal DNA elements in erlotinib-resistant GBM cells (Fig. 3D) . No changes in chromosomal EGFR copy number were detected between naïve, erlotinib-resistant, or drug-removed GBM cells. The overall FISH signal patterns were confirmed by analysis of more than 100 interphase nuclei from each of the three conditions ( fig. S7 ). The loss of EGFR + extrachromosomal DNA in erlotinib resistance was specific, because these cells still contained abundant extrachromosomal DNA elements ( fig. S6 ), including MDM2 + DMs, which were identified by FISH and polymerase chain reaction (PCR)-Southern blot analysis. The MDM2 + DM copy number rose with erlotinib treatment and remained elevated, even after drug withdrawal ( fig. S8 ). In each erlotinibresistant metaphase or interphase cell, a single 
specific centromere sequences, was detected. Similar HSR-like EGFR + marker chromosomes were detected in naïve and drug-removed GBM metaphases, raising the possibility that these bodies may serve as a latent reservoir for EGFRvIII in erlotinib-resistant GBM cells (Fig. 3D and fig. S9 ).
To confirm that the EGFR + extrachromosomal elements were EGFRvIII, we performed Southern blot, PCR, and sequencing analyses of lowmolecular-weight extrachromosomal DNA (Fig.  3, E to I) . A 4.1-kb band in BamH1-digested lowmolecular-weight DNA indicative of EGFRvIII was detected in naïve and drug-removed GBM39 cells but not erlotinib-resistant cells (Fig. 3, E and  F) . The intronic breakpoints that give rise to the EGFRvIII deletion are not consistent, varying between individuals (23). Therefore, we designed primers mapping at each of the 17 BamH1 restriction sites spanning the region of interest. PCR and Southern blot analyses identified a genomic deletion confirmed to be EGFRvIII by sequencing of cloned fragments ( fig. S10 and Fig. 3 , E to I). We identified the intronic breakpoints giving rise to EGFRvIII in two additional patient-derived GBM ex vivo neurosphere cultures (GBM6 and HK296) ( fig. S10) (24, 25) and measured extrachromosomal EGFRvIII DNA copy number in naïve and erlotinib-resistant cells, including after drug withdrawal, by a quantitative PCR assay. Consistent with the effect of erlotinib in GBM39 cells, continuous EGFR TKI treatment caused almost complete loss of extrachromosomal EGFRvIII DNA and erlotinib resistance (Fig. 4A and fig. S11 ). Remarkably, cessation of erlotinib treatment for as little as 72 hours in GBM6 and HK296 markedly increased extrachromosomal EGFRvIII DNA and resensitized tumor cells to erlotinib-induced cell death ( fig. S11) .
The availability of two pairs of matched formalinfixed, paraffin-embedded tissue sections from patients pre-and post-lapatinib treatment (patients 2 and 3 from Fig. 1, I and J) enabled us to perform FISH using probes for EGFR (which recognizes EGFRvIII) and centromere 7. In both patients, a nearly 80% reduction in EGFR FISHpositive signals after lapatinib treatment was detected (Fig. 4B) , thus indicating the clinical relevance of loss of extrachromosomal EGFRvIII DNA as an EGFR TKI resistance mechanism. In this cohort of patients, intratumoral lapatinib levels sufficient to cause tumor cell death (2000 to 3000 nM) were not achieved in the tumor samples (7). However, 1500 nM of lapatinib, an intratumoral level observed in at least some of these patients, was sufficient to cause highly significant reduction of extrachromosomal EGFRvIII DNA in GBM39, GBM6, and HK296 neurospheres in culture ( fig. S12) , suggesting that the significant reduction seen in patients 2 and 3 was a consequence of lapatinib treatment.
Analysis of an additional four matched sets of EGFRvIII-positive tumor tissue from GBM patients before and after treatment with conventional therapy (temozolomide and radiation) showed no detectable difference in extrachromosomal EGFR FISH-positive DNA levels (Fig. 4C) . Taken together, these results indicate that loss of extrachromosomal EGFRvIII DNA is a general and clinically relevant EGFR TKI resistance mechanism in GBM.
It is unusual for EGFRvIII to be homogeneously expressed in a tumor, despite the selective growth advantage conferred to individual GBM cells (Fig. 1, B, C, E, and F) . EGFRvIII possibly imposes a cost to tumor cells, potentially by increasing nutrient requirements (Fig. 1D) . Notably, the EGFR TKI resistance mechanism identified here is entirely distinct from the mechanism by which GBMs maintain EGFRvIII heterogeneity in the absence of treatment. Extrachromosomal EGFRvIII DNA copy number remains elevated in the treatment-naïve EGFRvIII Low cells ( fig. S13 ), consistent with an epigenetic regulatory mechanism of EGFRvIII heterogeneity (15) . Taken together, these results highlight the exquisite specificity of reversible loss of extrachromosomal EGFRvIII DNA as a GBM EGFR TKI resistance mechanism. 
EGFRvIII
High GBMs display enhanced apoptotic sensitivity to EGFR TKIs (Fig. 1F) . However, our data suggest that EGFR TKI resistance may not be mediated entirely by selection for a subpopulation of tumor cells lacking extrachromosomal EGFRvIII DNA but may also involve rapid single-step elimination, as has been described for loss of the DHFR gene on double minutes in the absence of methotrexate (26, 27) and the loss of MYCC or MYCN from double minutes in the presence of hydroxyurea (28) . These independent and complementary mechanisms of EGFRvIII regulation, coupled to intercellular signaling between EGFRvIII High /EGFRvIII
Low tumor cells (6) , enable GBMs to achieve an EGFRvIII High /EGFRvIII Low ratio that is optimal for growth and survival, including in response to EGFR TKI therapy. Future work is needed to examine the compensatory mechanisms that enable GBM cells lacking EGFRvIII extrachromosomal DNA to continue to proliferate during EGFR TKI treatment, including the potential role of extrachromosomal MDM2 amplification, and possible changes along the spectrum of epithelial mesenchymal transition, including irreversible up-regulation of ZEB-1 ( fig. S14 ), which recently has been shown to promote plasticity and tumorigenicty of breast cancer cells (29) .
Resistance to targeted therapies is a nearly universal clinical challenge for cancer patients (1, 3) . Daily dosing with the EGFR TKIs is not optimal because it is hard to achieve sufficient levels of intratumoral EGFR inhibition (7). Pulsatile intermittent treatment with much higher doses of an EGFR TKI could potentially lead to better target inhibition and even possibly less toxicity relative to continuous dosing. In other cancers, a "drug holiday" can resensitize tumors to targeted therapy (30) . The data presented here provide a conceptual mechanistic rationale for pulsatile intermittent EGFR TKI dosing in GBM to achieve better target inhibition while permitting tumors to regain drug sensitivity as extrachromosomal EGFRvIII DNA levels rapidly rise between treatments ( fig. S11) . These results provide an unexpected twist showing that loss of EGFRvIII extrachromosomal DNA promotes resistance, in contrast to the current paradigm of drug resistance through increased levels of extrachromosomal DNA carrying drug resistance genes (31, 32) . These results also highlight the diversity of mechanisms by which extrachromosomal DNA can promote resistance to targeted cancer therapies. A number of other oncogenes have been identified on extrachromosomal DNA (33) , potentially enabling them to respond rapidly to targeted drug treatment (34) . It is possible that resistance in other tumor types in which the main oncogene is extrachromosomal may be similarly mediated by loss of the oncogene on extrachromosomal DNA.
